Skip to contents

A longitudinal dataset designed to demonstrate event marker functionality. Shows multiple timeline segments per patient with different clinical events, treatments, and adverse event management.

Usage

data(swimmer_unified_events)

Format

A data frame with 20 rows and 8 variables:

PatientID

Character. Patient identifiers (multiple rows per patient)

StartTime

Numeric. Segment start time in months

EndTime

Numeric. Segment end time in months

Response

Character. Response during this segment (CR, PR, SD, PD)

EventType

Character. Type of clinical event (Treatment Start, Dose Escalation, etc.)

EventTime

Numeric. Time when the event occurred

Severity

Character. Event severity (None, Mild, Moderate, Severe)

Cycle

Numeric. Treatment cycle number

Source

Generated for ClinicoPath package demonstration

Examples

data(swimmer_unified_events)

# Event markers swimmer plot
swimmerplot(
  data = swimmer_unified_events,
  patientID = "PatientID",
  startTime = "StartTime", 
  endTime = "EndTime",
  responseVar = "Response",
  showEventMarkers = TRUE,
  eventVar = "EventType",
  eventTimeVar = "EventTime",
  markerSize = 6,
  plotTheme = "ggswim"
)
#> 
#>  SWIMMER PLOT
#> 
#>  <div style='color: #8a6d00; background-color: #fff8e1; padding: 15px;
#>  border: 1px solid #ffc107; border-radius: 5px; margin: 10px;'>
#> 
#>  Analysis Information
#> 
#>  Found 15 duplicate patient IDs. Multiple episodes per patient detected
#>  - this is normal for longitudinal data.
#> 
#>  Timeline Summary Statistics         
#>  ─────────────────────────────────── 
#>    Metric                Value       
#>  ─────────────────────────────────── 
#>    Number of Patients    10.000000   
#>    Total Observations    25.000000   
#>    Median Duration        9.500000   
#>    Mean Duration          9.700000   
#>    Total Person-Time     97.000000   
#>    Mean Follow-up         9.700000   
#>    CR Rate (%)           30.000000   
#>    PD Rate (%)           20.000000   
#>    PR Rate (%)           30.000000   
#>    SD Rate (%)           20.000000   
#>  ─────────────────────────────────── 
#> 
#> 
#>  <div style='background-color: #e8f5e8; padding: 15px; border-radius:
#>  5px; margin: 10px 0;'>
#> 
#>  Clinical Interpretation
#> 
#>  <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Timeline
#>  Analysis:
#> 
#>  Study included 10 patients with 25 timeline observations. Median
#>  follow-up was 9.5 months (range: 5.0 to 15.0 months).
#> 
#>  <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Person-Time
#>  Analysis:
#> 
#>  Total person-time: 97.0 months. Average follow-up per patient: 9.7
#>  months.
#> 
#>  <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Response
#>  Pattern Analysis:
#> 
#>  Most common response was CR (30.0% of observations). Response
#>  distribution shows clinical patterns suitable for efficacy analysis.
#> 
#>  Person-Time Analysis                                                          
#>  ───────────────────────────────────────────────────────────────────────────── 
#>    Response Type    Patients    Total Time    Mean Time    Follow-up Density   
#>  ───────────────────────────────────────────────────────────────────────────── 
#>    CR                      3      35.00000    11.670000             8.571000   
#>    PD                      2      16.00000     8.000000            12.500000   
#>    PR                      3      24.00000     8.000000            12.500000   
#>    SD                      2      22.00000    11.000000             9.091000   
#>  ───────────────────────────────────────────────────────────────────────────── 
#> 
#> 
#>  Milestone Event Summary                              
#>  ──────────────────────────────────────────────────── 
#>    Milestone    Events    Median Time    Time Range   
#>  ──────────────────────────────────────────────────── 
#>  ──────────────────────────────────────────────────── 
#> 
#> 
#>  Event Marker Summary                                          
#>  ───────────────────────────────────────────────────────────── 
#>    Event Type             Count    Percentage    Median Time   
#>  ───────────────────────────────────────────────────────────── 
#>    Dose Modification          6      24.00000       5.000000   
#>    Hospitalization            3      12.00000       5.000000   
#>    Response Assessment        5      20.00000       4.000000   
#>    Scan                       7      28.00000       4.000000   
#>    Toxicity                   4      16.00000       5.000000   
#>  ───────────────────────────────────────────────────────────── 
#> 
#> 
#>  Advanced Clinical Metrics                                                                                                                                       
#>  ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
#>    Metric                           Value        95% CI         Unit                 Clinical Interpretation                                                     
#>  ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
#>    Median Follow-up Time             9.500000                   months               Central tendency of patient follow-up duration                              
#>    Interquartile Range               4.500000                   months               Middle 50% of follow-up duration range                                      
#>    Total Study Person-Time          97.000000                   months cumulative    Total observation time across all patients                                  
#>    Follow-up Density                10.309000                   per 100 months       Number of patients per 100 units of observation time (descriptive metric)   
#>    Objective Response Rate (ORR)    60.000000    26.2 - 87.8    percent              Proportion with complete or partial response                                
#>    Disease Control Rate (DCR)       80.000000    44.4 - 97.5    percent              Proportion with response or stable disease                                  
#>  ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
#>